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Background: Vaccination is currently the most effective means of preventing influenza infection. Yet evidence of
vaccine performance, and the impact and value of seasonal influenza vaccination across risk groups and between
seasons, continue to generate much discussion. Moreover, vaccination coverage is below recommended levels.
Methods: A model was generated to assess the annual public health benefits and economic importance of
influenza vaccination in 5 WHO recommended vaccination target groups (children 6 – 23 months of age; persons
with underlying chronic health conditions; pregnant women; health care workers; and, the elderly, 65 years of age)
in 27 countries of the European Union. Model estimations were based on standard calculation methods, conservative
assumptions, age-based and country-specific data.
Results: Out of approximately 180 million Europeans for whom influenza vaccination is recommended, only about 80
million persons are vaccinated. Seasonal influenza vaccination currently prevents an annual average of between 1.6
million and 2.1 million cases of influenza, 45,300 to 65,600 hospitalizations, and 25,200 to 37,200 deaths. To reach the
75% vaccination coverage target set by the EU Council Recommendation in 2009, an additional 57.4 million person
would need to be vaccinated in the elderly and other risk groups. By achieving the 75% target rate set in EU-27
countries, average annual influenza- related events averted would increase from current levels to an additional +1.6
to +1.7 million cases, +23,800 to +31,400 hospitalization, +9,800 to +14,300 deaths, +678,500 to +767,800 physician
visits, and +883,800 to +1,015,100 lost days of work yearly. Influenza-related costs averted because of vaccination would
increase by an additional + €190 to + €226 million yearly, in vaccination target groups.
Conclusions: Full implementation of current influenza vaccination recommendations of 75% vaccination coverage rate
(VCR) in Europe by the 2014–2015 influenza season could immediately reduce an important public health and
economic burden.
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The global burden of influenza
Globally, the annual attack rate with influenza viruses
ranges between 5 to 10% in adults and 20 to 30% in chil-
dren [1]. Groups at particular risk of severe influenza
include pregnant women, children aged <5 years, the
elderly (65 years), and individuals with underlying health
conditions. Health care workers are at increased risk of* Correspondence: ssamson@spmsd.com
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transmission, particularly in patient care settings. The
WHO estimates that 3–5 million cases of severe influenza
illness occur every year resulting in 250,000-500,000
deaths worldwide, with most influenza deaths occurring
among adults over 65 years of age [2].The burden of influenza in Europe
In Europe, a rough estimate puts the average annual ex-
cess deaths from seasonal influenza at 38,500 with con-
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57.05/100,000 in Spain (1999 and 2005) [4] to 160/
100,000 in Slovakia (1982–2000) [5]. The impacts on
healthcare costs and productivity are substantial [6].
Ryan et al. estimated that 100% vaccination coverage in
risk groups in France, Germany, Italy, Spain, and the UK
would result in a savings of €1.59 billion in reduced hos-
pitalizations alone [7]. In 2012–2013, the influenza sea-
son in Europe was unusually long, peaking in week 5 of
2013 and ending with a late rise in influenza B cases in
many countries [8,9]. Based on data from 13 European
countries or regions, excess mortality for the winter was
higher than in the previous 3 influenza seasons, espe-
cially in the elderly (65 years) [9]. Influenza-related GP
visits in France were approximately twice the number
from the previous season (10.2 million vs. 3.5 million)
and 1 out of 3 children were affected [10]. The impact
on health spending was also significant with one esti-
mate putting the cost of influenza in France at € for
doctors’ fees, pharmaceuticals, and compensation for
sick-days for the month of January 2013 alone and €220
million for the season by the end of March 2013 [11,12].
The total impact of an influenza epidemic (including dir-
ect and indirect costs) in industrialised countries has
been estimated to reach € [13]. Extrapolating from the
estimated costs of the 1996–1997 influenza epidemic in
Germany (approximately € million), and a French esti-
mate of an annual € million in costs, the costs in the EU
would range from €6 billion to €14 billion annually.
The importance of influenza vaccination
Vaccination is currently the most effective means of pre-
venting influenza infection. Inactivated seasonal influ-
enza vaccines were first licensed in 1945 [14]. Now,
several influenza vaccines, including live attenuated or
inactivated quadrivalent vaccines in conventional or
alternate delivery forms, and adjuvanted vaccines are
available. The World Health Organization’s (WHO) pos-
ition on currently licensed influenza vaccines is that they
are safe and efficacious and can prevent significant an-
nual morbidity and mortality [1]. Likewise, the European
Centre for Disease Prevention and Control (ECDC)
strongly advocates the use of currently licensed influenza
vaccines among those for whom they are recommended
[15]. Influenza vaccination strategies in Europe typically
target groups at greater risk of complications. As such,
the EU Council has recommended that member states
achieve vaccination coverage rates (VCRs) of 75% in the
elderly and, if possible, in other risk groups, and health
care workers by the 2014–2015 influenza season [16].
However, vaccination coverage remains suboptimal.
Yet evidence of vaccine performance, and the impact
and value of seasonal influenza vaccination across risk
groups and between seasons, continue to generate muchdiscussion. Despite the Council recommendation [16],
VCRs in Europe have not increased since 2009 and there
is evidence of declining trends across all EU member
States [17,18]. This is in part because comparable and
consolidated evidence is scarce.
What our study addresses
We generated a model to assess the public health bene-
fits and economic importance of influenza vaccination in
the 5 WHO recommended vaccination target groups
(children 6 – 23 months of age; persons with underlying
chronic health conditions; pregnant women, health care
workers; and, the elderly, 65 years of age) [1] in 27 coun-
tries of the European Union (Austria, Belgium, Bulgaria,
Cyprus, Czech Republic, Denmark, Estonia, France,
Finland, Germany, Greece, Hungary, Ireland, Italy, Latvia,
Lithuania. Luxembourg, Malta, Netherlands, Poland,
Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, UK)
(EU-27), using available values for vaccine efficacy or ef-
fectiveness and available vaccine coverage rates. Our as-
sessment included an evaluation of the potential benefits
of vaccination at the EU Council recommended 75% vac-
cination coverage level.
Methods
Our approach was adapted from the model published by
Ryan et al. who estimated the potential benefits from sea-
sonal influenza vaccination in Europe with 100% vaccin-
ation coverage [7]. Our model estimations were based on
standard calculation methods, conservative assumptions,
age-based and country-specific data. We estimated the
number of eligible person in different risk groups who
would need to be vaccinated to achieve the 75% vaccination
coverage target in 27 EU countries. The numbers of avert-
able influenza-related events and the associated offset costs
were estimated in 8 countries (the UK, Germany, Italy,
Spain, France, Poland, Slovakia, Sweden) and extrapolated
to the EU-27 at current and at 75% VCR. Different values
for efficacy and effectiveness of influenza vaccine were used
to test the sensitivity of these parameters on the results.
Estimates
Estimating the vaccination gap to achieve 75% vaccination
coverage
We estimated the vaccination coverage gap for each of
27 countries, by target group. This was achieved by sub-
tracting the number of people actually vaccinated for in-
fluenza in each country from the number of people
potentially eligible for influenza vaccination under the
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against influenza virus in priority group r living in coun-
try c (according to the official sources) per year; Vc,r(75%)
is the number of people that are expected to be vacci-
nated against influenza virus, according to 75% target in
each country and priority group, per year.
Target groups considered, using the EU Council and
WHO 2012 recommended groups definitions, were: chil-
dren 6 – 23 months of age; persons with underlying
chronic health conditions (chronic respiratory condi-
tions, cardiovascular disease, diabetes, renal disease,
suppressed immunity, lung cancer, and liver disease);
pregnant women; health care workers; and, the elderly
(65 years of age for all countries except Germany where
60 years was used).
Estimating avertable burden of seasonal influenza
The public health burden of influenza in this study was
defined by the following attributes: the numbers of influ-
enza cases, physician visits, hospitalizations, lost days of
work, and deaths. Avertable economic burdens were
assessed by the costs of general practitioner (GP) visits,
hospitalizations, lost days of work, and total costs avoided.
We refer to these attributes individually as influenza-
related events.
To minimize the impact of methodological bias, dis-
tinct estimates were calculated for the numbers of
influenza-related events avoided using effectiveness or
efficacy values. Effectiveness values reflect actual per-
formance of the vaccine, under programmatic condi-
tions, against laboratory confirmed flu cases.
Efficacy values provide the best quality evidence be-
cause they are generated from randomised controlled
trials measuring incidence of laboratory-confirmed influ-
enza in vaccination and placebo groups, but the results
are scarce for some populations.
Avertable influenza-related events were then estimated
by applying the country-specific annual incidence rate of
the influenza related event to the unvaccinated eligible
population and multiplying the effectiveness value of the




  Er  Ic;r
Where Vc,r and Vc,r(75%) have the same meaning as in
formula above; Er is effectiveness of vaccine in prevent-
ing influenza cases for priority group r; Icr is the priority
group and country-specific incidence of influenza in un-
vaccinated population.
This method was used to estimate the number of
avertable influenza-related events at existing VCRs, and
at a 75% coverage rate.To account for the fact that available epidemiological in-
formation was collected in countries where significant
proportions of individuals are protected against influenza
because of vaccination, the expected rate of influenza-
related events in the unvaccinated was calculated as:
The observed rate of influenza-related events in
the vaccinated/(1 − Vaccination Coverage × Vaccination
Effectiveness).
The cost of avertable influenza-related events was esti-
mated by applying a country-specific unit cost to the
total number of influenza related events estimated.
Data sources
European and especially local data sources are scarce
and not available for each country, by season and by spe-
cific populations. When needed, extrapolations were
done and are described below.
Vaccination coverage rates (VCR)
VCR data used came from the ECDC (VENICE survey)
influenza vaccination surveys, if available, to ensure
methodological consistency [19-21]. When information
for specific target groups was incomplete, alternate
sources were used [22-29]. Most of the data was avail-
able for children, the elderly and health care workers.
For missing data, extrapolation from other countries was
performed by using an average VCR for all countries in
a given target group where the VCR information was
available. Where data was missing for pregnant women,
the general population VCR values – where available -
were adopted. This information was available for 12
countries. The values for HCW VCR were adopted for 7
more countries whilst the rest were extrapolated from
elsewhere. The VCR for people with chronic diseases
group was available for 16 countries .When VCR for this
group was missing, the VCR for the elderly from the
same country was used (which was always available).
In all cases, only seasonal VCRs for the regular influenza
seasons - and never on pandemic vaccine coverage – were
collected. Generally, data from the latest year was taken,
unless it was from a pandemic year. However, if the only
available VCR was from the pandemic year, it was also ac-
ceptable and used, as long as it was for seasonal vaccine
coverage. The range of years from which data was ex-
tracted was for the 2003–2004 to 2009–2010 influenza
seasons, the most up-to-date at the time of the analysis
Vaccine effectiveness
Effectiveness values were taken from a large case–con-
trol study conducted by the US Centers for Disease Con-
trol and Prevention (CDC) in the 2010–11 influenza
season enrolling 1,048 cases aged 6 months and up, and
in 3,768 controls [30] (Table 1). This study was selected
as the method used was very strong and it provides
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groups, in the absence of a single equivalent European
source. These values were supplemented with lower and
upper values of effectiveness collected from I-MOVE, a
European network supported by ECDC that measures
the effectiveness of influenza vaccines against laboratory
confirmed influenza. The data came from the 2010–
2011 [31] and 2011–2012 seasons [32]. These values
were selected to reflect the differences that can be ob-
served across flu seasons. It was assumed that the inci-
dence of all influenza- related events would be reduced
in the same proportion as the probability of laboratory-
confirmed influenza (LCI).
Vaccine efficacy
Efficacy values were taken from Cochrane systematic re-
views comparing inactivated trivalent influenza vaccines
with placebo [33-35] (Table 1). Only values of efficacy
for LCI, from randomised controlled trials (RCTs), were
used. It was assumed that the incidence of all influenza-
related events would be reduced in the same proportion
as the probability of LCI. For the upper and lower limits
used, we chose the confidence intervals on the meta-
analysis. For the group of children 6 – 23 months, the
upper and lower confidence limits were very wide (−69 –
82) [33] so these were substituted with 25 and 65 respect-
ively: the lower limit was chosen to be consistent with the
difference between the mean and lower limit in the elderly
group, while the upper limit was chosen to be comparable
with the efficacy values observed in healthy adults.
Influenza attack rates
The influenza target-group-specific attack rates were de-
rived from the weighted average of influenza incidence
in the placebo arms of 29 Cochrane reviewed RCTs
worldwide: 9 articles for children; 2 for the elderly; and,18 for healthy adults. It was assumed that the age-
specific average annual rate of true influenza was equal
to the weighted average of influenza incidence in the
placebo arm. The same age-specific attack rates were ap-
plied across all countries (Table 2).
Epidemiological data
Since methodological differences exist in EU-wide na-
tional influenza surveillance systems, a sample of 8 coun-
tries (France, Germany, the UK, Spain, Italy, Sweden,
Poland and Slovakia) (EU-8) was selected and values were
extrapolated to the remaining 19 countries (Table 2) based
on 4 geographical regions. The average values for epi-
demiological burden data from France, Germany and the
UK were applied to Austria, Belgium, Ireland, Luxembourg,
the Netherlands; values for Sweden were applied to
Denmark and Finland; average values for Italy and Spain
were applied to Cyprus, Greece, Malta, Portugal, Slovenia;
and, average values for Poland and Slovakia were applied
to Bulgaria, Czech Republic, Estonia, Hungary, Latvia,
Lithuania, Romania. The EU-8 countries represent more
than 70% of the total population of the EU-27, and 7 of
these account for 72% of the vaccination gap. Country-
specific missing data were usually replaced by similar data
from neighboring countries or from another risk group in
the same country. For instance, when country specific in-
formation on influenza-related mortality rates were not
available, rates were extrapolated from Czech Republic for
Poland and Slovakia, and from Norway for Sweden. For
missing data in the underlying chronic health conditions
group, the coverage rate for the elderly from the same
country was applied. For missing data in other target
groups, the average coverage rates from all other countries
were applied.
Epidemiological data varied by country but was usually
available for years ranging from 2000 – 2011, except for
Table 2 Age specific data used in the model for each country or for all EU-27
Data used
for modeling
Vaccination target group Germany France Italy Spain UK Poland Slovakia Sweden EU-27
Influenza attack
rate
6-23 months 19.10% 19.10% 19.10% 19.10% 19.10% 19.10% 19.10% 19.10% 19.10%
Healthy, 2–64 years
(health care workers and
pregnant women)
3.64% 3.64% 3.64% 3.64% 3.64% 3.64% 3.64% 3.64% 3.64%
Underlying chronic conditions,
2–64 yrs
3.64% 3.64% 3.64% 3.64% 3.64% 3.64% 3.64% 3.64% 3.64%
Elderly 4.91% 4.91% 4.91% 4.91% 4.91% 4.91% 4.91% 4.91% 4.91%
Influenza-related
GP visits rate
6-23 months 5.99% 5.20% 5.97% 3.45% 7.21% 2.97% 5.40% 2.05%
Healthy, 2–64 years
(health care workers and
pregnant women)
2.35% 2.04% 2.25% 1.35% 1.18% 1.17% 2.34% 2.55%
Underlying chronic conditions,
2–64 yrs
2.35% 2.04% 2.25% 1.35% 1.18% 1.17% 2.34% 2.55%




6-23 months 127.90 73.70 76.90 67.60 131.10 134.70 205.50 106.10
Healthy, 2–64 years
(health care workers and
pregnant women)
12.70 7.30 7.60 6.70 4.90 13.30 20.30 10.50
Underlying chronic conditions,
2–64 yrs
34.30 19.80 20.60 18.10 17.90 36.10 55.10 28.50
Elderly 179.50 103.40 107.90 94.90 130.00 189.00 288.40 148.90
Influenza-related
mortality/100,000
6-23 months 1.62 0.80 0.83 1.09 1.28 2.02 3.07 1.93
Healthy, 2–64 years
(health care workers and
pregnant women
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Underlying chronic conditions,
2–64 yrs
4.90 4.86 5.06 2.31 3.87 6.10 9.28 5.84
Elderly 84.70 84.00 87.50 57.05 66.90 105.00 160.55 101.00
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and GP visits for which the range was 1986 – 2011.
General Practitioner (GP) visits
Data on influenza-related GP visits was captured from
country-specific surveillance. Only the UK had age-
specific data on influenza related GP visits. Age-specific
estimates in other countries were based on the propor-
tion of age-specific influenza-like-illnesses (ILI) rates. In
countries where information was available on ILI-related
GP visits (rather than on influenza), it was assumed that
ILI incidence was 3.65 times higher than influenza inci-
dence. The constant is the ratio of ILI to influenza rates
from a Cochrane Review that pooled data from 12 RCT
studies (weighting for sample size) and included a total
of 13,242 healthy adults reporting both incidence of ILI
and influenza in their placebo arms [34].
Hospitalizations
Hospitalizations avoided were estimated using excess all-
cause influenza-related hospitalization rates. For the UK,data from Pitman et al. [36] were used whereas in the
other countries rates were estimated based on age-specific
rates of all-cause influenza-related hospitalizations from
the Netherlands [37]. Age-specific estimates from the
Netherlands were extrapolated to other European coun-
tries with adjustment according to the ratio of the annual
incidence of hospitalisations with a primary diagnosis of
acute upper respiratory infection and influenza in each
country over the incidence in the Netherlands. Estimates
of annual incidence of hospitalization with a primary diag-
nosis of upper respiratory infections and influenza were
sourced from Eurostat [22].
Mortality
Data on excess all-cause influenza-related mortality, for
all age groups combined, was available for Germany
[38], Italy [39] and the UK [40]. Influenza-related mor-
tality for all age groups combined using country-specific
methods by authors in the literature were then derived
from these. In the absence of age-specific data, age-
specific mortality rates were calculated assuming the
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groups was similar to the distribution reported in Norway
[41], the only European source of age-specific data identi-
fied. The influenza-related mortality rate among people
with underlying chronic health conditions was assumed to
be the same as for people aged 45–65 in the general popu-
lation, and mortality was assumed to be 0 amongst preg-
nant women (out of pandemic period) and healthcare
workers. For Poland, Slovakia and Sweden, where data on
influenza-related mortality rates were not available, rates
were extrapolated from the Czech Republic, Poland and
Norway respectively, with adjustment according to the
age-specific relative rates of hospitalization between coun-
tries. This was done to moderate any difference in mag-
nitude between the rates of influenza-related events
between two countries. Similarly for France and Spain,
influenza-attributable mortality rates were extrapolated
from Italy, with adjustment according to age-specific ra-
tios of annual incidences of hospitalizations with primary
diagnoses of acute respiratory infection and influenza be-
tween those countries and Italy. The data for Italy were
from Rizzo et al. [39].
Lost work days
These were estimated to occur both for parents attend-
ing to sick children and for illness amongst working
adults. The number of potentially preventable missed
working days for parents who take care of sick children
was estimated as the number of potentially preventable
GP visits associated with influenza for children under 2,
multiplied by the employment adjustment (since in some
cases parents will not be working, and therefore no work
days will be missed), the number of days missed in case
of absence, and the probability of absence among cases
with GP consultation. OECD statistics on employment
rates were used, representing the population of working
age (15–64 years). The expected number of days taken off
work for adults in this study was estimated as the product
of the probability of taking time off (91% for sickness from
influenza), [42] and the average duration of time off for in-
fluenza sickness, 4 days [42,43]. This was applied to all
countries and for all adult target groups.
Economic data
Country-specific unit costs were available for 8 countries
(Germany, France, Italy, Spain, the UK, Poland, Slovakia,
Sweden) and extrapolated to the remaining 19 by match-
ing each against one of the EU-8 reference countries
judged to be most similar in terms of health system:
Germany served as a reference for Austria; France
served as a reference for Belgium, Luxembourg, and the
Netherlands; Slovakia served as a reference for Bulgaria,
Czech Republic, Estonia, Hungary, Latvia, Lithuania,
Romania, and Slovenia; Spain served as a reference forCyprus, Greece, Malta, and Portugal; Sweden served as a
reference for Denmark and Finland; and the UK served
as a reference for Ireland. Italy and Poland did not serve
as references.
Estimates were made for the costs of GP visits, hospi-
talizations and lost wages.
GP costs for influenza-related visits
These were country-specific and estimated to be the
same for all age and risk groups except in France where
the cost of physician visits is higher for children than for
adults [44-51].
Hospitalization costs for influenza related illness
Hospitalization costs were obtained from diagnostic re-
lated group (DRG) tariffs or hospitalization statistics in dif-
ferent countries, except for Poland, where a cost from the
literature was used [50]. For each age group, a weighted
average cost was calculated, with weights equal to the pro-
portions of different diagnoses (upper respiratory tract in-
fections (URTI); lower respiratory tract infections and
pulmonary disease (LRTI); cardiovascular diseases (CVD)
and other complications) as reported by Jansen et al. [37].
Lost wages
To estimate the total value of work-related monetary losses,
the number of potentially preventable days missed from
work per country was multiplied by the monetary value of
each missed working day using OECD statistics [47].
Total offset costs
The total cost offsets for EU-27 were calculated by com-
bining the costs avoided per country, by risk group, for
GP visits, hospitalization and for lost wages due to ab-
senteeism from work. Total costs were estimated for
current VCR and 75% VCR for all risk groups. Estimates




Target groups for influenza vaccination represent 36% of
the EU-27 population, amounting to approximately 180
million persons eligible for vaccination. The break down
by age-specific groups and by country is shown in
Figure 1. Among recommended target groups for influ-
enza vaccination, the elderly (persons over 65) account
for 48% of all targeted groups, whereas 41% are persons
with underlying chronic health conditions (2 to 64 years).
Children, healthcare workers, and pregnant women rep-
resent the remaining 5%, 4% and 2% respectively.
Only about 80 million persons (44% of the eligible) in
EU-27 are vaccinated annually. None of the EU-27 coun-
tries has achieved the EU Council’s target of 75% coverage.
Figure 1 Population for whom influenza vaccination is recommended in 27 EU countries.
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countries, such as Estonia, achieving as little as 1% VCR
in the elderly target group.To reach a 75% vaccination
coverage target, an additional 57.4 million people would
need to be vaccinated (Figure 2). Fifty percent of the vac-
cination gap is constituted by persons with underlying
chronic health conditions (2 to 64 years), 29% by the eld-
erly, 9% by children 6–23 months, 7% by healthcare
workers, and 5% by pregnant women. However, the eld-
erly represent the largest target group for seasonal influ-
enza vaccination (47% of the eligible population) and have
the highest rates of influenza- related complications in-
cluding death. Therefore, the elderly constitute a particu-
larly important target group for improved vaccination
coverage, especially in the countries where coverage in
this target group is very low, such as in Eastern Europe.
Estimated averted burden with current vaccination
coverage rates
The vaccination target-specific estimates for averted
influenza-related events at current VCR in EU-8, repre-
senting more than 70% of the population of the EU-27,are shown in Table 3. Using efficacy values, 70% of cases
averted were in the elderly, 25% in persons with under-
lying chronic health conditions, and about 3% in children,
1% in healthcare workers, and <1% in pregnant women.
For GP visits averted, the elderly accounted for 57%
and persons with underlying chronic health condi-
tions for 38%. Ninety-two percent of averted hospi-
talizations and 98% of averted deaths were in the
elderly, whereas and 7% and 2% respectively were in
persons with underlying chronic health conditions.
But for lost work days averted, the chronically ill
group accounted for 92%.
Extrapolating to EU-27 at current VCR (Table 4), using
vaccine effectiveness and vaccine efficacy values respect-
ively, we estimated that seasonal influenza vaccination
currently prevents an average of between 1.6 million and
2.1 million cases of influenza each year. Average annual
GP visits, hospitalizations, deaths, and lost days of work
averted were estimated at: 701,200 to 916,000; 45,300 to
65,600; 25,200 to 37,200; and, 715,400 to 844,700, respect-
ively. The corresponding costs avoided for GP visits, hos-
pitalizations and lost days of work were estimated at
Figure 2 Actual number versus 75% VCR versus 100% VCR vaccinated in 27 EU countries.
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million; and, €96 million to €113 million respectively.
Estimated benefits of reaching 75% vaccination coverage
rate
Using vaccine effectiveness and vaccine efficacy values
respectively, we estimated that increasing the VCR to
75% in EU-27 countries would avert an average add-
itional +1.6 million to +1.7 million cases yearly over cur-
rently averted cases.
Additional avertable average annual GP visits, hospi-
talizations, death and lost days of work were estimated
at: +678,500 to +767,800, +23,800 to +31,400, +9,800
to +14,300, and +883,800 to +1,015,100 respectively. The
corresponding additional costs averted were estimatedTable 3 Vaccination target-specific averted influenza-related
Slovakia, Sweden and Germany) using efficacy values at curr
Influenza-related events averted 6 – 23 months Elderly C
cases (%) 55,626 (3.3) 1,178,452 (70.0)
GP visits (%) 17,585 (2.4) 423,686 (57.1)
Hospitalizations (%) 333 (0.6) 50,706 (92.5)
Deaths (%) 3 (0.0) 30,238 (97.7)
Days of work lost (%) 9,492 (1.6) 0at: + €20 million to + €23 million for GP visits, + €57
million to + €75 million for hospitalizations, and + €112
million to + €128 million for lost days of work. Total
influenza-related costs would be offset by + €190 million
to + €226 million yearly, in recommended vaccination
target groups (Table 5).
The analysis from the EU-8 countries shows that rais-
ing VCR would increase the number of cases averted
most in the group of persons with underlying chronic
conditions (+38%) and in the 6–24 month group (+27%).
For GP visits and lost days of work, 52% of visits and
76% of lost days of work are avoided in persons with
underlying chronic conditions. However, the majority of
avertable hospitalizations and deaths occur for the eld-
erly (70% and 91% respectively).events, in EU-8 countries (France, Italy, Spain, UK, Poland,
ent VCR
hronically ill Healthcare workers Pregnant women Totals
418,050 (24.8) 21,046 (1.2) 11,026 (0.7) 1,684,200
280,906 (37.9) 13,342 (1.8) 6,604 (0.9) 742,123
3,704 (6.8) 60 (0.1) 29 (0.1) 54,832
705 (2.3) 0 0 30,946
558,516 (92.0) 26,713 (4.4) 12,650 (2.1) 607,371
Table 4 Estimated public health and economic impacts of seasonal trivalent influenza vaccination extrapolated to
EU-27 countries
Influenza-related event Numbers and costs currently averted at existing VCR (lower, upper limit)
Estimates using effectiveness values Estimates using efficacy values
Numbers of events averted Costs averted Number of events averted Costs averted
Cases of influenza 1.6 million (0.82; 2.2) - 2.1 million (1.3; 2.6) -
Influenza-related mortality 25,161 (10,092; 38,390) - 37,165 (21,986; 44,667) -
Influenza- related GP visits 701,234 (417,680; 958,010) €22 million (13; 30) 915,997 (620,643; 1,110,498) €29 million (20; 35)
Influenza-related hospitalization 45,325 (19,440; 67,970) €131 million (56;197) 65,593 (39,536; 82,036) €190 million (141; 238)
Lost days of work 715,428 (568,878; 881,851) €96 million (76; 118) 844,748 (661,843; 973,075) €113 million (88; 130)
All Influenza-related costs - €248 million (145; 345) - €332 million (222; 403)
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Our model estimated that seasonal influenza vaccination
in Europe currently averts each year between 1.6 to 2.1
million cases, and prevent between 25,200 and 37,200
deaths, with corresponding significant impact on hospita-
lisations, GP visits and costs avoided (between €248 and
€332 million saved annually). The number of avertable
events was within a same range regardless if effectiveness
or efficacy values were used and the benefits were sub-
stantive even at the lowest estimated values, supporting
the strong public health interest of influenza prevention.
Raising the VCR from current levels in Europe to the
recommended 75% target, in all WHO- recommended
vaccination target groups, would avert an additional
average annual +1.6 to +1.7 million cases, +678,482
to +767,787 physician visits, +23,793 to +31,350
hospitalization, +9,843 to +14,342 deaths, and +883,750
to 1,015,145 lost days of work. Influenza-related costs
would be offset by an additional + €190 to + €226 mil-
lion over currently averted costs.
While the purpose of our study was not to estimate
the net budget impact of influenza vaccination, our re-
sults are complementary to the WHO position [1] and
to recent papers demonstrating that influenza vaccination
is cost effective or even cost-savings in EU countries
[52,53]. Estimating the cost of increasing vaccination
coverage will be very specific to the healthcare system. InTable 5 Estimated additional (+) impacts of seasonal trivalen
Influenza-related event Numbers and costs averted addi
Estimates using effectiveness
Number of events averted Cos
Cases of influenza +1.6 million (0.85; 2.0)
Influenza-related mortality +9,843 (4,185; 14,831)
Influenza- related GP visits +678,482 (424,321; 849,284) +€20 m
Influenza-related hospitalization +23,792 (11,199; 33,525) +€ 57 m
Lost days of work +883,750 (671,094; 1,081,253) +€112 m
All Influenza-related costs - +€190 msome countries, increasing coverage using existing infra-
structure will require minimum investments compared to
the net public health and economic savings generated. In
other countries, particularly where vaccination coverage is
very low, a greater initial investment will be necessarily
but it will also improve access to preventive services for
the most vulnerable. Where additional resources are re-
quired to achieve the recommended 75% VCR, countries
should consider who is currently covering the curative
costs of influenza because those payors will have the
greatest incentive to invest in prevention.
It has been argued that increased effectiveness/efficacy
of seasonal influenza vaccines is needed [15]. We esti-
mated the impact of a hypothetical vaccine with 80% ef-
fectiveness/efficacy compared to the impact of increasing
vaccination coverage with current trivalent influenza vac-
cines to 75%. Overall, the impacts were similar but this
does not consider the possible impact that increasing vac-
cine effectiveness might have on vaccination acceptance.
Furthermore, there are challenges associated with achiev-
ing 80% vaccine effectiveness, particularly in the elderly
with immuno-senescence, and with seasonal strain drift,
and with vaccine strain mismatches. Further vaccine
research and development is ongoing to overcome the as-
sociated challenges, but in the meantime increasing cover-
age with existing vaccines remain the best present
solution to fight against a preventable disease.t influenza vaccination extrapolated to EU-27
tional (+) to currently averted events if VCR is increased to 75%
(lower, upper limit)
values Estimates using efficacy values
ts averted Number of events averted Costs averted
- +1.7 million (1.1; 2.1) -
- +14,342 (8,620; 17,939) -
illion (13; 25) +767,787 (543,913; 935,732) +€23 million (16; 28)
illion (28; 81) +31,350 (19,545; 39,254) +€75 million (47; 94)
illion (85; 137) +1,015,145 (783,557; 1,184,489) +€128 million (99;150)
illion (125; 243) - +€226 million (162;272)
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a simplified approach was used which did not account
for the indirect benefits of influenza vaccination linked
to herd immunity. This underestimates the potential
benefits of influenza vaccination. The model also only
estimated some of the indirect costs (from work days
lost) and some of the direct costs (GP visits and hospita-
lisations), providing underestimated figure of the pos-
sible economic benefits.
Additional limits relate to lack of data in EU and
country-specific data and the methods used to account for
missing data. The choice of estimating average values
across seasons was clearly driven by the absence of season
specific data and aimed at reflecting an estimate of influ-
enza vaccination benefits across years. Different sources
were taken for effectiveness and efficacy to account for
variability between seasons and sources, and results were
described accordingly however they might not be relevant
for seasons with extreme viral circulation or vaccine mis-
match. The model also did not account for the impact of
increasing vaccination coverage which can result in a de-
creasing risk in the unvaccinated and decrease vaccine ef-
fectiveness, but this impact is expected to be small.
To deal with local data scarcity, country-specific miss-
ing data were usually replaced by similar data from
neighboring countries or from another risk group in the
same country, and for missing data in other target
groups, the average coverage rates from all other coun-
tries were applied. This may lead to an overestimate of
current VCR in the chronically ill group, for these coun-
tries, meaning that annual benefits from seasonal vaccin-
ation might be overestimated but meaning also that the
benefits from increasing VCR and raising EU Council
recommendation are underestimated. On the other
hand, the use of incidence data on influenza-related events
from surveillance networks in countries may underesti-
mate the actual number of GP visits, since not all events
will have been detected.
Kastova et al. [54] conducted a similar study to ours in
the US. They collected surveillance data from six influ-
enza seasons in the US. They defined impact as both the
number of averted outcomes and the prevented disease
fraction. Presenting impact as the prevented disease frac-
tion allows to control for the relative severity of different
seasons. They showed that a greater fraction of disease
was prevented as greater fractions of the population
were vaccinated.
As in our model, Kastova et al. used an annual vaccine
effectiveness estimate based on the range of available
vaccine effectiveness estimates in the literature for each
season. They also performed sensitivity analyses around
their assumptions for missing data to account for un-
certainty. In their study, influenza illnesses averted by
vaccination ranged from approximately 1.1 million to 5million (or 357 – 1,641 per 100,000 population) during a
season while the number of averted hospitalizations
ranged from a 7,700 to 40,400 (2 – 13 per 100,000). This
compares with an estimate from our study of approxi-
mately 311 – 409 averted cases and 9 – 13 averted hos-
pitalizations per 100,000 population in Europe. Our
findings are corroborated by those of Kastova et al. who
found that influenza vaccination programs produce a
substantial health benefit in terms of averted cases, clinic
visits, hospitalizations, and deaths. Both Kastova et al.
and our model support the need for improvements in
vaccination coverage among non- elderly persons and
improvements in vaccine effectiveness among the elderly
to improve vaccination program effectiveness.
Conclusions
Our model reveals that, in spite of currently low vaccine
coverage and less than expected vaccine effectiveness,
the public health impact and offset costs are important.
The results complete evidence of influenza vaccination
cost-effectiveness and provide significant figures of an-
nual burden prevented. Both public health and economic
benefits from seasonal influenza vaccination can be sig-
nificantly increased if the 75% vaccination coverage rate
is reached: twice as many cases could be prevented and
hundreds of thousands of hospitalizations and physicians
visits could be avoided, reducing the burden on health-
care systems. In a context of ageing population, crowed
healthcare systems, and budget constraints, the eco-
nomic savings from a reduction in the costs of influenza
disease and deaths are important to consider.
To achieve the 2014–2015 EU Council recommenda-
tion for seasonal influenza vaccine coverage in Europe,
public health officials and the healthcare community
should remove the barriers that underpin suboptimal im-
plementation of national/EU recommendations on sea-
sonal influenza vaccination based on the findings from
previous studies [55], and find innovative and effective
ways to improve access of European citizens to influenza
vaccination delivery and health care professionals (such as
vaccination at pharmacies or in shopping centers). Our
model highlights the need for program options to be de-
signed to better cover specific target groups and for coun-
tries to implement evidence-based vaccination policies.
In parallel, the medical community and the vaccine in-
dustry should continue to invest in research and develop-
ment (R&D) to develop novel influenza vaccines. There
are over 200 clinical trials ongoing in influenza of which
about 25% are in phase I or II, and over 100 biotechnology
companies working on influenza [56]. Adjuvanted, intra-
dermal, and nasal spray vaccines are available for the up-
coming influenza season and new live attenuated and
inactivated quadrivalent influenza vaccines are licensed in
the US [57] and EU.
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development of influenza vaccines are complementary
approaches and will better protect European population
from seasonal influenza epidemics. Full implementation
of current influenza vaccination recommendations could
immediately reduce the burden of seasonal influenza in-
fections and increase efficiencies in allocation of health
resources and boost economic growth by preventing loss
of productivity and preserving health.
Expanding coverage to additional vaccination target
groups, as has been done in the US, and more recently
the UK, would also increase the benefits. With the suc-
cessful development of new and improved vaccines, still
more benefits can be achieved in the future.
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